Nuvation Bio Inc.

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

NUVB$4.20-3.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited, In thousands, except per share data)

	For the Three Months Ended March 31,
	2025	2024
Revenue	$3,084	$—
Cost of revenue	2,094	—
Gross profit	990	—
Operating expenses:
Research and development	24,601	12,842
Selling, general and administrative	35,393	7,357
Total operating expenses	59,994	20,199
Loss from operations	(59,004)	(20,199)
Other income (expense):
Interest income	5,321	7,130
Interest expense	(54)	—
Investment advisory fees	(203)	(265)
Change in fair value of warrant liability	(751)	(1,459)
Realized gain on marketable securities	3	1
Other income	1,452	—
Total other income (expense), net	5,768	5,407
Loss before income taxes	(53,236)	(14,792)
Provision for income taxes	—	—
Net loss	$(53,236)	$(14,792)
Net loss per share attributable to common stockholders, basic and diluted	$(0.16)	$(0.07)
Weighted average common shares outstanding, basic and diluted	338,612	219,048
Comprehensive loss:
Net loss	$(53,236)	$(14,792)
Other comprehensive loss, net of taxes:
Currency translation adjustment	465	—
Unrealized loss on available-for-sale securities	(493)	(1,350)
Comprehensive loss	$(53,264)	$(16,142)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.